Event-Driven Stocks

IDENIX PHARMACEUTICALS INC

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

Signs● 1 good● 5 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY13FY12FY11FY10FY09
Revenue$852,000$35.6M$7.0M$10.2M$12.6M
Operating income−$123.7M−$35.4M−$53.4M−$62.7M−$54.4M
Net income−$30.8M$11.4M−$52.0M−$61.6M−$53.2M
Total assets$141.0M$250.9M$141.0M$69.9M—
Total liabilities$35.0M$31.7M$89.8M$101.0M—
Equity$106.0M$219.2M$51.2M−$31.1M−$5.5M
EPS (diluted)—$0.10———
Shares out.134.0M107.6M107.2M73.1M—

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2013
Operating margin
−14521.1%
Net margin
−3609.5%
Return on equity
−29.0%
Return on assets
−21.8%
Return on capital (ROCE)
−100.7%
Liabilities / assets
24.8%
Debt / equity
0.33×
Book value / share
$0.79
Revenue growth (YoY)
−97.6%
Net income growth (YoY)
−368.6%

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2013
Altman Z″ (distress)
-16.73distress
Accruals / assets
55.5%high accruals
Piotroski F-Score
0/9weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
22
/ 100
Profitability 0Growth 0Catalyst 33Earnings quality 0Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 5 warning● 1 good
  • Altman Z″ in the distress zone
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Revenue declined year-over-year
  • Negative operating cash flow
  • High accruals — earnings-quality risk
  • Conservative leverage (liabilities < 50% of assets)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Insider transactions

SEC Form 4 · most recent
0 acquisitions2 disposalsnet −86.7M shares · last 2
InsiderDateTypeSharesPrice
Baupost Group Llc/Ma10% ownerAug 5, 2014J53.3M$24.50
Novartis Pharma Ag10% ownerAug 5, 2014U33.3M$24.50

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)